ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Currently, it is difficult to diagnose Alzheime's disease (AD) and predict its progression with certainty. This multicenter study will look at the usefulness of brain imaging and other biological tests (biomarkers) in detecting AD and its progression. Participants will include older adults with either: 1) early AD, 2) normal memory and thinking, or 3) mild cognitive impairment (MCI), a condition that often represents a transitional state between normal aging and AD. Subjects will undergo interviews and examinations, cognitive testing, and brain magnetic resonance imaging (MRI) at approximately 6-month intervals for 2-3 years. Blood and urine samples will be collected. A subset of subjects will also undergo serial positron emission tomography (PET) brain imaging. Cerebrospinal fluid will be collected twice during the study from those subjects agreeing to have a lumbar puncture. Information and samples collected from participants at all sites will be stored centrally and made available to help researchers design future studies to treat or prevent Alzheimer's disease.